Taro Pharmaceutical Industries Ltd.

NYSE:TARO Stock Report

Market Cap: US$1.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Taro Pharmaceutical Industries Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Uday Baldota

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.8yrs
CEO ownershipn/a
Management average tenure8.8yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

Taro Pharmaceutical Industries Ltd. Is An Overlooked Opportunity

Dec 12

Taro Pharmaceutical: Sun Pharma Deal Uncertain, No Discernible Value Beyond NAV (Rating Downgrade)

Aug 16

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Jun 02

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Feb 24

Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M

Jan 24

Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $30.52M

Oct 28

Taro Pharmaceutical hits 52-week low; down 28% YTD

Aug 15

Taro Pharmaceutical Non-GAAP EPS of $1.09 beats by $0.24, revenue of $156.7M beats by $6.8M

Jul 27

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

Jul 14

We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

Aug 03
We Think Taro Pharmaceutical Industries' (NYSE:TARO) Healthy Earnings Might Be Conservative

A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

Jan 26
A Look At Taro Pharmaceutical Industries' (NYSE:TARO) Share Price Returns

CEO

Uday Baldota (54 yo)

6.8yrs
Tenure

Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...

Leadership Team

NamePositionTenureCompensationOwnership
Uday Baldota
CEO & Director6.8yrsno datano data
William Coote
VP, CFO & Chief Accounting Officer2.5yrsno datano data
Itamar Karsenti
VP & Head of Operations9.5yrsno datano data
Avi Avramoff
VP and Head of R&D12.7yrsno datano data
Itzik Baruch
Vice President of Technical Services14.4yrsno datano data
Roman Kaplan
Vice President of Scientific and Technical Compliance Managerno datano datano data
Erik Zwicker
VP, General Counsel & Secretary4.2yrsno datano data
Ara Aprahamian
Vice President of Sales & Marketing11.3yrsUS$616.14kno data
Michele Visosky
VP & Head of Human Resourceno datano datano data
Jayesh Shah
Head of Procurement12.5yrsno datano data
Richard Glaze
VP & Head of Information Technology8yrsno datano data
Ori Gutwerg
VP & Head of U.S. Generics Rx5.2yrsno datano data
8.8yrs
Average Tenure
58yo
Average Age

Experienced Management: TARO's management team is seasoned and experienced (8.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Uday Baldota
CEO & Director7.5yrsno datano data
Dilip Shanghvi
Chairman of the Board10.9yrsUS$1.00mno data
Robert Stein
Independent Director4.3yrsno datano data
Sudhir Valia
Director13.8yrsUS$500.00kno data
James Kedrowski
Director13.1yrsno datano data
Linda Shushan
Independent Director7.5yrsno datano data
Abhay Gandhi
Vice Chairman7.5yrsno datano data
Oded Sarig
Independent Director1yrno datano data
7.5yrs
Average Tenure
68yo
Average Age

Experienced Board: TARO's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/06/24 11:26
End of Day Share Price 2024/06/24 00:00
Earnings2024/03/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Taro Pharmaceutical Industries Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Randall StanickyGoldman Sachs
Raghuram SelvarajuH.C. Wainwright & Co.
Kenneth CacciatoreTD Cowen